# Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)

> **NCT02406222** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Leeds** · enrollment: 124 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Pomalidomide
- **DRUG:** Dexamethasone
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT02406222
- **Lead sponsor:** University of Leeds
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-03
- **Primary completion:** 2022-12
- **Final completion:** 2025-06
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2024-12-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02406222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02406222, "Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02406222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*